Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis
- PMID: 830579
Serum lipids, insulin, and glucagon after portacaval shunt in cirrhosis
Abstract
The cholesterol-lowering effect of portacaval anastomosis in homozygous familial hypercholesterolemia suggested a study of lipid metabolism in cirrhotic patients after portasystemic anastomoses. Fasting serum cholesterol, triglycerides, insulin, and glucagon levels were obtained in 20 patients with alcoholic cirrhosis and portacaval anastomosis, and in 21 nonshunted subjects with cirrhosis. After 100 g of glucose, given orally, insulin and glucagon levels were measured. In the shunted patients serum cholesterol was higher than in the nonshunted subjects, 240 +/- 15 mg per 100 ml (mean +/- 1 SEM) versus 180 +/- 13 mg per 100 ml, P less than 0.01. Triglycerides were normal in both groups. Fasting insulin was elevated to a greater extent in the shunted patients with cirrhosis (36 +/- 5 muU per ml) than in the nonshunted patients (22 +/- 4 muU per ml), P less than 0.05. Two hours after glucose, insulin levels were also elevated to a greater extent in the shunted subjects (304 +/- 50 muU per ml) than in the nonshunted subjects (167 +/- 29 muU per ml), P less than 0.03. Fasting glucagon (corrected for interference factor) was elevated to a greater extent in the shunted subjects (204 +/- 35 pg per ml) than in the nonshunted subjects (80 +/- 19 pg per ml), P less than 0.01. The explanation for serum cholesterol elevation after surgical shunting in cirrhotics is unknown. Two possible hypotheses--the differential action of insulin and glucagon on cholesterol metabolism and the effects of shunting on the cirrhotic liver--are discussed.
Similar articles
-
Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.Gastroenterology. 1978 Jun;74(6):1224-8. Gastroenterology. 1978. PMID: 648812
-
Glucose tolerance after portacaval shunt in liver cirrhosis.Diabete Metab. 1986 Aug;12(4):197-202. Diabete Metab. 1986. PMID: 3533668
-
Pancreatic glucoregulatory hormones in cirrhosis of the liver: portal vein concentrations during intravenous glucose tolerance test and in response to a meal.Diabete Metab. 1980 Jun;6(2):117-27. Diabete Metab. 1980. PMID: 6997101
-
Hormonal and metabolic changes in hepatic cirrhosis.Horm Metab Res. 1982 Jan;14(1):34-9. doi: 10.1055/s-2007-1018914. Horm Metab Res. 1982. PMID: 7037586
-
Early and late changes in fasting and absorptive plasma amino acids and ammonia after distal splenorenal shunt in cirrhosis.Hepatology. 1994 Feb;19(2):329-38. Hepatology. 1994. PMID: 8294090 Clinical Trial.
Cited by
-
Serum levels of true insulin, C-peptide and proinsulin in peripheral blood of patients with cirrhosis.Diabetologia. 1983 Dec;25(6):506-9. doi: 10.1007/BF00284460. Diabetologia. 1983. PMID: 6363178
-
Plasma pancreatic glucagon in pancreatic and primary diabetes, and liver cirrhosis: application of a correction to the radioimmunoassay for pancreatic glucagon.Gastroenterol Jpn. 1982;17(4):347-52. doi: 10.1007/BF02774581. Gastroenterol Jpn. 1982. PMID: 7141199
-
Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis.Diabetologia. 1979 Jul;17(1):23-8. doi: 10.1007/BF01222973. Diabetologia. 1979. PMID: 467851 No abstract available.
-
Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect.J Clin Invest. 1985 May;75(5):1659-65. doi: 10.1172/JCI111873. J Clin Invest. 1985. PMID: 3889056 Free PMC article.
-
Effect of somatostatin (SRIF) on plasma glucose and insulin response to glucagon in liver cirrhosis.Acta Diabetol Lat. 1979 Apr-Jun;16(2):139-45. doi: 10.1007/BF02581093. Acta Diabetol Lat. 1979. PMID: 484163
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical